Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group

Noriyoshi Iriyama, Shin Fujisawa, Chikashi Yoshida, Hisashi Wakita, Shigeru Chiba, Shinichiro Okamoto, Kimihiro Kawakami, Naoki Takezako, Takashi Kumagai, Koiti Inokuchi, Kazuma Ohyashiki, Jun Taguchi, Shingo Yano, Tadahiko Igarashi, Yasuji Kouzai, Satoshi Morita, Junichi Sakamoto, Hisashi Sakamaki

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

To investigate the factors that affect molecular responses on dasatinib treatment in patients with chronic-phase chronic myeloid leukemia (CML-CP), we performed a clinical trial named the "D-First study." Fifty-two patients with newly diagnosed CML-CP were enrolled in this study and received 100 mg dasatinib once daily. A deep molecular response (DMR) was defined as <50 copies/μg RNA of BCR-ABL1 transcript value corrected by GAPDH, which ensures <0.01% of BCR-ABL1 transcript value according to International Scale (BCR-ABL1IS). The halving time for BCR-ABL1 transcripts was calculated using transcript levels before dasatinib treatment, transcript levels after 3 months of treatment, and the treatment time between these two points. In terms of molecular response, 38 of 51 (75%) patients reached major molecular response (MMR) by 12 months, and the rate of DMR by 18 months was 59% (30/51). While both BCR-ABL1 transcript levels before treatment and a shorter halving time of BCR-ABL1 transcripts (≤14 days) were significant factors affecting achievement of MMR by 12 months, the Sokal score at diagnosis was not associated with MMR. Importantly, the halving time was the only factor that predicted achievement of DMR by 18 months. We showed that patients with CML-CP treated with dasatinib can be stratified according to the early treatment response as determined by the halving time of BCR-ABL1 transcripts. These data emphasize the significance of the early response from dasatinib treatment in achieving a DMR.

Original languageEnglish
Pages (from-to)282-287
Number of pages6
JournalAmerican Journal of Hematology
Volume90
Issue number4
DOIs
Publication statusPublished - 2015 Apr 1

Fingerprint

Leukemia, Myeloid, Chronic Phase
Therapeutics
Dasatinib
Clinical Trials
RNA

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib : Results of the D-first study of Kanto CML study group. / Iriyama, Noriyoshi; Fujisawa, Shin; Yoshida, Chikashi; Wakita, Hisashi; Chiba, Shigeru; Okamoto, Shinichiro; Kawakami, Kimihiro; Takezako, Naoki; Kumagai, Takashi; Inokuchi, Koiti; Ohyashiki, Kazuma; Taguchi, Jun; Yano, Shingo; Igarashi, Tadahiko; Kouzai, Yasuji; Morita, Satoshi; Sakamoto, Junichi; Sakamaki, Hisashi.

In: American Journal of Hematology, Vol. 90, No. 4, 01.04.2015, p. 282-287.

Research output: Contribution to journalArticle

Iriyama, N, Fujisawa, S, Yoshida, C, Wakita, H, Chiba, S, Okamoto, S, Kawakami, K, Takezako, N, Kumagai, T, Inokuchi, K, Ohyashiki, K, Taguchi, J, Yano, S, Igarashi, T, Kouzai, Y, Morita, S, Sakamoto, J & Sakamaki, H 2015, 'Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group', American Journal of Hematology, vol. 90, no. 4, pp. 282-287. https://doi.org/10.1002/ajh.23923
Iriyama, Noriyoshi ; Fujisawa, Shin ; Yoshida, Chikashi ; Wakita, Hisashi ; Chiba, Shigeru ; Okamoto, Shinichiro ; Kawakami, Kimihiro ; Takezako, Naoki ; Kumagai, Takashi ; Inokuchi, Koiti ; Ohyashiki, Kazuma ; Taguchi, Jun ; Yano, Shingo ; Igarashi, Tadahiko ; Kouzai, Yasuji ; Morita, Satoshi ; Sakamoto, Junichi ; Sakamaki, Hisashi. / Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib : Results of the D-first study of Kanto CML study group. In: American Journal of Hematology. 2015 ; Vol. 90, No. 4. pp. 282-287.
@article{5d91807cfa4c48d0860f958bfbf5ac0d,
title = "Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group",
abstract = "To investigate the factors that affect molecular responses on dasatinib treatment in patients with chronic-phase chronic myeloid leukemia (CML-CP), we performed a clinical trial named the {"}D-First study.{"} Fifty-two patients with newly diagnosed CML-CP were enrolled in this study and received 100 mg dasatinib once daily. A deep molecular response (DMR) was defined as <50 copies/μg RNA of BCR-ABL1 transcript value corrected by GAPDH, which ensures <0.01{\%} of BCR-ABL1 transcript value according to International Scale (BCR-ABL1IS). The halving time for BCR-ABL1 transcripts was calculated using transcript levels before dasatinib treatment, transcript levels after 3 months of treatment, and the treatment time between these two points. In terms of molecular response, 38 of 51 (75{\%}) patients reached major molecular response (MMR) by 12 months, and the rate of DMR by 18 months was 59{\%} (30/51). While both BCR-ABL1 transcript levels before treatment and a shorter halving time of BCR-ABL1 transcripts (≤14 days) were significant factors affecting achievement of MMR by 12 months, the Sokal score at diagnosis was not associated with MMR. Importantly, the halving time was the only factor that predicted achievement of DMR by 18 months. We showed that patients with CML-CP treated with dasatinib can be stratified according to the early treatment response as determined by the halving time of BCR-ABL1 transcripts. These data emphasize the significance of the early response from dasatinib treatment in achieving a DMR.",
author = "Noriyoshi Iriyama and Shin Fujisawa and Chikashi Yoshida and Hisashi Wakita and Shigeru Chiba and Shinichiro Okamoto and Kimihiro Kawakami and Naoki Takezako and Takashi Kumagai and Koiti Inokuchi and Kazuma Ohyashiki and Jun Taguchi and Shingo Yano and Tadahiko Igarashi and Yasuji Kouzai and Satoshi Morita and Junichi Sakamoto and Hisashi Sakamaki",
year = "2015",
month = "4",
day = "1",
doi = "10.1002/ajh.23923",
language = "English",
volume = "90",
pages = "282--287",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib

T2 - Results of the D-first study of Kanto CML study group

AU - Iriyama, Noriyoshi

AU - Fujisawa, Shin

AU - Yoshida, Chikashi

AU - Wakita, Hisashi

AU - Chiba, Shigeru

AU - Okamoto, Shinichiro

AU - Kawakami, Kimihiro

AU - Takezako, Naoki

AU - Kumagai, Takashi

AU - Inokuchi, Koiti

AU - Ohyashiki, Kazuma

AU - Taguchi, Jun

AU - Yano, Shingo

AU - Igarashi, Tadahiko

AU - Kouzai, Yasuji

AU - Morita, Satoshi

AU - Sakamoto, Junichi

AU - Sakamaki, Hisashi

PY - 2015/4/1

Y1 - 2015/4/1

N2 - To investigate the factors that affect molecular responses on dasatinib treatment in patients with chronic-phase chronic myeloid leukemia (CML-CP), we performed a clinical trial named the "D-First study." Fifty-two patients with newly diagnosed CML-CP were enrolled in this study and received 100 mg dasatinib once daily. A deep molecular response (DMR) was defined as <50 copies/μg RNA of BCR-ABL1 transcript value corrected by GAPDH, which ensures <0.01% of BCR-ABL1 transcript value according to International Scale (BCR-ABL1IS). The halving time for BCR-ABL1 transcripts was calculated using transcript levels before dasatinib treatment, transcript levels after 3 months of treatment, and the treatment time between these two points. In terms of molecular response, 38 of 51 (75%) patients reached major molecular response (MMR) by 12 months, and the rate of DMR by 18 months was 59% (30/51). While both BCR-ABL1 transcript levels before treatment and a shorter halving time of BCR-ABL1 transcripts (≤14 days) were significant factors affecting achievement of MMR by 12 months, the Sokal score at diagnosis was not associated with MMR. Importantly, the halving time was the only factor that predicted achievement of DMR by 18 months. We showed that patients with CML-CP treated with dasatinib can be stratified according to the early treatment response as determined by the halving time of BCR-ABL1 transcripts. These data emphasize the significance of the early response from dasatinib treatment in achieving a DMR.

AB - To investigate the factors that affect molecular responses on dasatinib treatment in patients with chronic-phase chronic myeloid leukemia (CML-CP), we performed a clinical trial named the "D-First study." Fifty-two patients with newly diagnosed CML-CP were enrolled in this study and received 100 mg dasatinib once daily. A deep molecular response (DMR) was defined as <50 copies/μg RNA of BCR-ABL1 transcript value corrected by GAPDH, which ensures <0.01% of BCR-ABL1 transcript value according to International Scale (BCR-ABL1IS). The halving time for BCR-ABL1 transcripts was calculated using transcript levels before dasatinib treatment, transcript levels after 3 months of treatment, and the treatment time between these two points. In terms of molecular response, 38 of 51 (75%) patients reached major molecular response (MMR) by 12 months, and the rate of DMR by 18 months was 59% (30/51). While both BCR-ABL1 transcript levels before treatment and a shorter halving time of BCR-ABL1 transcripts (≤14 days) were significant factors affecting achievement of MMR by 12 months, the Sokal score at diagnosis was not associated with MMR. Importantly, the halving time was the only factor that predicted achievement of DMR by 18 months. We showed that patients with CML-CP treated with dasatinib can be stratified according to the early treatment response as determined by the halving time of BCR-ABL1 transcripts. These data emphasize the significance of the early response from dasatinib treatment in achieving a DMR.

UR - http://www.scopus.com/inward/record.url?scp=84925365783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925365783&partnerID=8YFLogxK

U2 - 10.1002/ajh.23923

DO - 10.1002/ajh.23923

M3 - Article

C2 - 25530131

AN - SCOPUS:84925365783

VL - 90

SP - 282

EP - 287

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -